 announces the opening of their new, dedicated Neuropsychiatric Research Center in Overland Park, KS. This research facility supports the needs of the pharmaceutical and biotechnology sectors by providing effective study recruitment, medical management and oversight in study volunteers across a range of neuropsychiatric disorders including both acute and chronic schizophrenia.

“While Vince and Associates has been conducting clinical trials in schizophrenia over the past decade, this dedicated unit will allow us to better serve the needs of both study volunteers and our biopharmaceutical clients,” said Dr. Brad Vince, President and Medical Director.

Debra Kelsh, MD, a Board-Certified Psychiatrist and an Investigator in over 300 clinical trials, will serve as Medical Director of the new Neuropsychiatric Research Center. “The safety and security of our study volunteers was highly emphasized during the design of the unit,” said Dr. Kelsh.